Continuing Royalty Obligations Sample Clauses

Continuing Royalty Obligations. Early termination of this Agreement does not relieve Company and its Affiliates and Sublicensees from payments to NU in accordance with Article 4 should Company and its Affiliates or Sublicensees continue to lease, sell, or otherwise generate revenue from the Licensed Products. Such obligations shall survive, in full force and effect, for the original term of this Agreement.
Sample 1Sample 2
AutoNDA by SimpleDocs
Continuing Royalty Obligations. From and after the date hereof, Sheffield may, solely or in conjunction with a third party sublicensee or commercial partner, continue development activities with respect to the Sublicensed Patent Rights and the Technology in the Field. In the event that certain products, described on Exhibit B, reach commercialization as a direct result of any prior development efforts conducted by Inpharzam under the Sublicense Agreement, Inpharzam shall be entitled to royalties derived from such products, if any, as set forth on Exhibit B. Except with respect to the stock repurchase and royalty obligations set forth herein, and the repayment of the Line of Credit Loan, and except as otherwise expressly set forth in this Amendment or the Sublicense Agreement, as amended hereby, Sheffield shall have no further obligation to make payments of any type to Inpharzam from and after the date of execution and delivery of this Amendment.
Sample 1Sample 2
Continuing Royalty Obligations. Notwithstanding Section 7.1 and Section 7.2 above, CTIPAC's obligations to pay Assignor the Continuing Royalty shall continue (i) beyond the Term to the extent that any Net Proceeds are received after the expiration of the Term, and (ii) after any Purchase Amount termination, provided that any Net Proceeds are received after such termination.
Sample 1

Related to Continuing Royalty Obligations

  • Royalty Obligations Part 2.7(e) of the Disclosure Schedule contains a complete and accurate list and summary of all royalties, fees, commissions, and other amounts payable by the Seller to any Person (other than sales commissions paid to employees according to the Seller’s standard commissions plan) upon or for the sale, or distribution of any Seller Product or the use of any Seller IP.

  • Duration of Royalty Obligations The royalty obligations of Licensee as to each Product shall terminate on a country-by-country and product-by-product basis concurrently with the expiration of:

  • Third Party Obligations 3.1. The THIRD PARTY shall:-

  • Specific Obligations The HSP:

  • Valid Obligations The execution, delivery and performance of the Loan Documents have been duly authorized by all necessary corporate action and each represents a legal, valid and binding obligation of Borrower and is fully enforceable according to its terms, except as limited by laws relating to the enforcement of creditors' rights.

  • Payments and Royalties 6.1 RIGEL shall upon the Effective Date:

  • Fees and Royalties The parties hereto understand that the fees and royalties payable by LICENSEE to UNIVERSITY under this Agreement are partial consideration for the license granted herein to LICENSEE under Patent Rights. LICENSEE shall pay UNIVERSITY:

  • Supply Obligations Upon Licensor’s request, AbbVie shall either (a) to the extent allowable under such agreements, assign to Licensee or its Affiliates the portion of AbbVie’s agreement(s) with its Third Party manufacturing provider related to the Terminated Antibodies, Terminated Products and placebo used in connection therewith, or alternatively, use Commercially Reasonable Efforts to facilitate Licensor’s entering into a direct supply agreement with such Third Party manufacturing provider of the Terminated Antibodies, Terminated Products and placebo used in connection therewith on comparable terms to those between AbbVie and such Third Party manufacturing provider (in each case assuming AbbVie is then obtaining supply of Terminated Antibodies, Terminated Products or placebo used in connection therewith from a Third Party manufacturing provider) and (b) to the extent AbbVie or its Affiliate is producing its own supply of the Terminated Product, Terminated Antibody or placebo, use Commercially Reasonable Efforts to supply to Licensor the Terminated Antibodies and/or Terminated Products and placebo as requested by Licensor, to the extent reasonably necessary for Licensor’s continued Development and Commercialization of such Terminated Antibodies and/or Terminated Products, until the date on which Licensor notifies AbbVie in writing that Licensor has secured an alternative manufacturer for the Terminated Antibodies and/or Terminated Products, but in no event more for than [***] after the effective date of any expiration or termination of this Agreement. In the case of (b), Licensor shall pay to AbbVie a transfer price for the materials supplied equal to the Manufacturing Cost thereof. Without limiting the foregoing, in either case Licensor shall additionally have the right to immediately have AbbVie commence the transfer of the Manufacturing Process to Licensor or its designee, with such transfer to be carried out in accordance with the terms of Section 3.5.3, applied mutatis mutandis. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.

  • Payment of Leasehold Obligations Each Borrower shall at all times pay, when and as due, its rental obligations under all leases under which it is a tenant, and shall otherwise comply, in all material respects, with all other terms of such leases and keep them in full force and effect and, at Agent’s request will provide evidence of having done so.

  • Obligation to Pay Royalties A royalty is due Stanford under this Agreement for any activity conducted under the licenses granted. For convenience’s sake, the amount of that royalty is calculated using Net Sales. Nonetheless, if certain Licensed Products are made, used, imported, or offered for sale before the date this Agreement terminates, and those Licensed Products are sold after the termination date, ***** will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of those Licensed Products.

Time is Money Join Law Insider Premium to draft better contracts faster.